RxDoctor Payments Data

Adam Cirlincione, DPM

Podiatrist · Glen Cove, NYNPI 1720063720

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Royal Biologics, Inc. at 32.3% of the total. Reporting peaked in 2019 at $9,192 and has fallen 78.4% since, to $1,988 in 2025. Among podiatrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,735in general payments, 2019–2025

Across 314 payments — averaging $97.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Royal Biologics, Inc.$10K
  • Gramercy Extremity Orthopedics LLC$6K
  • Musculoskeletal Transplant Foundation Inc.$3K
  • Gotham Surgical Solutions & Devices, Inc.$1K
  • Smith+Nephew$1K
  • Next Science LLC$1K
  • plus $9K from 41 others

What the payments were for

  • Royalty or licence$6532%
  • Consulting fees$10,13333%
  • Speaking & faculty fees$1,2004%
  • Food & beverage$17,54957%
  • Education$1,2004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,735 in reported general payments places this provider in the 95th percentile of 862 podiatrist providers in New York.

See all podiatrist providers in New York

Medicare billing

Part B allowed, 2024
$121,651
Medicare patients
358
Services billed
1,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.25$10,608
Ketoconazole92$2,011
Ciclopirox26$460
Ammonium Lactate22$404
Mupirocin25$151
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$130
Methylprednisolone16$118
Gabapentin11$82
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,192$10,60825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 862 podiatrist providers in New York.

Other podiatrist in Glen Cove

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →